Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial
MT newswire2026/10/07 09:0105:01 AM EDT, 10/07/2026 (MT Newswires) -- Enliven Therapeutics (ELVN) is on track to start its phase 3 trial of relcobatinib in patients with previously treated chronic myeloid leukemia before the end of 2026, the company said Wednesday. The move comes after the company aligned with the US Food and Drug Administration on the trial's final design. The trial is designed to directly compare relcobatinib with second-generation tyrosine kinase inhibitors and is expected to enroll 450 adults with chronic myeloid leukemia. The primary endpoint is major molecular response at week 24, the company said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
